<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the page on muscular dystrophies!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Muscular Dystrophies</h1>
        <p>Muscular dystrophies represent a heterogeneous group of inherited <b>myopathic disorders</b> characterized by progressive <b>muscle weakness</b> and <b>degeneration</b> due to defects in various proteins crucial for muscle integrity. These conditions share the common pathological feature of ongoing <b>muscle fiber necrosis</b> and <b>regeneration</b>, ultimately leading to replacement by fibrous and adipose tissue.</p>

        <h2>Anatomical Considerations</h2>
        <p>The <b>sarcolemma</b>, or muscle cell membrane, is stabilized by a complex of proteins that link the intracellular cytoskeleton (particularly actin) to the extracellular matrix. This <b>dystrophin-glycoprotein complex</b> (DGC) serves as a shock absorber during muscle contraction. Disruption of any component of this complex leads to membrane instability, calcium influx, and eventual fiber necrosis.</p>

        <h2>Historical Perspective</h2>
        <p>The first description of muscular dystrophy dates back to 1836 by <b>Gaetano Conte</b>, but it was <b>Guillaume Duchenne</b> who provided the classic description of Duchenne muscular dystrophy (DMD) in 1861. The discovery of <b>dystrophin</b> in 1987 by Louis Kunkel revolutionized our understanding of these disorders.</p>

        <h2>Pathophysiological Classification</h2>
        <p>Muscular dystrophies can be classified based on the affected protein:</p>
        <ol>
            <li><b>Sarcolemmal proteins</b> (e.g., dystrophin in DMD/Becker)</li>
            <li><b>Nuclear envelope proteins</b> (e.g., emerin in Emery-Dreifuss)</li>
            <li><b>Extracellular matrix proteins</b> (e.g., laminin α2 in congenital MD)</li>
            <li><b>Sarcomeric proteins</b> (e.g., titin in tibial MD)</li>
            <li><b>Enzymes</b> (e.g., fukutin-related protein in LGMD)</li>
        </ol>

        <h2>Clinical Presentations</h2>
        <p>The presentation varies widely based on the specific dystrophy:</p>
        <ol>
            <li><b>Proximal weakness</b> (most common pattern, seen in DMD, Becker, LGMD)</li>
            <li><b>Distal weakness</b> (e.g., FSHD, Miyoshi myopathy)</li>
            <li><b>Oculopharyngeal</b> (ptosis and dysphagia predominant)</li>
            <li><b>Cardiomyopathy-predominant</b> (e.g., Emery-Dreifuss)</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following is the primary function of the dystrophin-glycoprotein complex in muscle fibers?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Generation of action potentials</li>
            <li data-answer="correct">Stabilization of the sarcolemma during contraction</li>
            <li data-answer="wrong">Synthesis of acetylcholine receptors</li>
            <li data-answer="wrong">Regulation of calcium release from the sarcoplasmic reticulum</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>A 5-year-old boy presents with frequent falls and difficulty running. On examination, he has calf hypertrophy and uses Gowers' maneuver to stand up. Which historical figure first described this condition?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">James Parkinson</li>
            <li data-answer="wrong">Jean-Martin Charcot</li>
            <li data-answer="correct">Guillaume Duchenne</li>
            <li data-answer="wrong">Alois Alzheimer</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Duchenne Muscular Dystrophy (DMD)</h1>
        
        <h2>Aetiology</h2>
        <p>DMD is caused by <b>mutations in the DMD gene</b> located at Xp21.2, which encodes the protein <b>dystrophin</b>. About 70% of cases are due to <b>large deletions</b>, 10% to duplications, and 20% to point mutations. The mutations result in a <b>frameshift</b> that prevents production of functional dystrophin.</p>

        <h2>Epidemiology</h2>
        <p>DMD has an incidence of approximately <b>1 in 3,500-5,000 male births</b>. It follows an <b>X-linked recessive</b> pattern, though about 30% of cases result from de novo mutations. Female carriers may manifest mild symptoms due to skewed X-inactivation.</p>

        <h2>Pathophysiology</h2>
        <p>The absence of dystrophin leads to:</p>
        <ol>
            <li>Disruption of the DGC, causing <b>sarcolemmal instability</b></li>
            <li>Abnormal calcium influx and <b>protease activation</b></li>
            <li>Repeated cycles of <b>necrosis and regeneration</b> until regenerative capacity is exhausted</li>
            <li>Replacement by <b>fibrosis and fat</b></li>
        </ol>

        <h2>Symptoms and Signs</h2>
        <p>The clinical course follows a predictable progression:</p>
        <ol>
            <li><b>Early childhood (2-5 years):</b> Delayed motor milestones, frequent falls, difficulty running/jumping</li>
            <li><b>School age (6-12 years):</b> Progressive proximal weakness, Gowers' sign, waddling gait, calf pseudohypertrophy</li>
            <li><b>Adolescence (13+ years):</b> Loss of ambulation (typically by age 12), scoliosis, respiratory insufficiency</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: DMD Presentation</b> - <i>"3 F's and a C"</i><br>
            <b>F</b>requent falls<br>
            <b>F</b>atigability<br>
            <b>F</b>irm calves (pseudohypertrophy)<br>
            <b>C</b>ognitive impairment (average IQ ~1 SD below mean)
        </div>

        <h2>Diagnosis</h2>
        <p>The diagnostic workup includes:</p>
        <ol>
            <li><b>Serum CK:</b> Markedly elevated (10-100x normal) even in presymptomatic stage</li>
            <li><b>Genetic testing:</b> Multiplex ligation-dependent probe amplification (MLPA) first-line to detect deletions/duplications</li>
            <li><b>Muscle biopsy:</b> Shows variation in fiber size, necrosis, regeneration, and absent dystrophin staining</li>
            <li><b>EMG:</b> Myopathic pattern with early recruitment of small, polyphasic units</li>
        </ol>

        <h2>Treatment</h2>
        <p>Management is multidisciplinary and includes:</p>
        <ol>
            <li><b>Corticosteroids:</b> Prednisone (0.75 mg/kg/day) or deflazacort shown to prolong ambulation by 2-5 years</li>
            <li><b>Cardiac:</b> ACE inhibitors/ARBs initiated once EF <55% or by age 10</li>
            <li><b>Respiratory:</b> Nocturnal BiPAP when FVC <50%, cough assist devices</li>
            <li><b>Orthopedic:</b> Spinal fusion for scoliosis >25°, tendon releases</li>
            <li><b>Emerging therapies:</b> Exon-skipping (e.g., eteplirsen for exon 51), stop codon read-through (ataluren)</li>
        </ol>

        <h2>Complications</h2>
        <p>Major complications include:</p>
        <ol>
            <li><b>Cardiomyopathy:</b> Present in all patients by age 18, leading cause of death</li>
            <li><b>Respiratory failure:</b> Due to diaphragmatic weakness and scoliosis</li>
            <li><b>Contractures:</b> Achilles, iliotibial band, elbow flexors</li>
            <li><b>Endocrine:</b> Growth retardation, adrenal suppression from steroids, osteoporosis</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>A 4-year-old boy has a serum CK of 15,000 U/L. Which genetic testing method is most appropriate as first-line for suspected DMD?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Sanger sequencing of the entire DMD gene</li>
            <li data-answer="correct">MLPA for deletions/duplications</li>
            <li data-answer="wrong">Whole exome sequencing</li>
            <li data-answer="wrong">Karyotype analysis</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>Which of the following is the most common cardiac manifestation in DMD patients by late adolescence?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Atrial fibrillation</li>
            <li data-answer="wrong">Pericardial effusion</li>
            <li data-answer="correct">Dilated cardiomyopathy</li>
            <li data-answer="wrong">Hypertrophic cardiomyopathy</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Becker Muscular Dystrophy (BMD)</h1>
        
        <h2>Aetiology</h2>
        <p>BMD is allelic to DMD, also caused by mutations in the <b>DMD gene</b>. However, these mutations are <b>in-frame deletions/duplications</b> or missense mutations that allow production of a <b>partially functional dystrophin</b> protein. The reading frame hypothesis explains the phenotypic difference between DMD (out-of-frame) and BMD (in-frame).</p>

        <h2>Epidemiology</h2>
        <p>BMD has an incidence of approximately <b>1 in 18,000 male births</b>. Like DMD, it follows <b>X-linked recessive</b> inheritance. The milder phenotype means some cases may go undiagnosed until adulthood.</p>

        <h2>Pathophysiology</h2>
        <p>The partially functional dystrophin leads to:</p>
        <ol>
            <li>Reduced but not absent <b>DGC stabilization</b></li>
            <li>Slower progression of <b>muscle damage</b></li>
            <li>Later onset of <b>fibrofatty replacement</b></li>
        </ol>

        <h2>Symptoms and Signs</h2>
        <p>BMD presents with:</p>
        <ol>
            <li><b>Later onset</b> (typically 5-15 years vs. 2-5 in DMD)</li>
            <li><b>Slower progression</b> (ambulation often preserved into 20s-40s)</li>
            <li><b>Calf pseudohypertrophy</b> (similar to DMD)</li>
            <li><b>Cardiomyopathy</b> that may be disproportionate to skeletal weakness</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: BMD vs. DMD</b> - <i>"Later, Longer, Less"</i><br>
            <b>Later</b> onset (school age vs. preschool)<br>
            <b>Longer</b> ambulation (into adulthood vs. loss by ~12)<br>
            <b>Less</b> severe cognitive impairment
        </div>

        <h2>Diagnosis</h2>
        <p>Similar to DMD but with important distinctions:</p>
        <ol>
            <li><b>Serum CK:</b> Elevated but may be less dramatic than DMD (5-20x normal)</li>
            <li><b>Genetic testing:</b> Same approach as DMD, but mutations preserve reading frame</li>
            <li><b>Muscle biopsy:</b> Shows dystrophic changes but with <b>patchy dystrophin staining</b> (vs. absent in DMD)</li>
        </ol>

        <h2>Treatment</h2>
        <p>Management principles:</p>
        <ol>
            <li><b>Corticosteroids:</b> Evidence less robust than for DMD, but may be considered</li>
            <li><b>Cardiac surveillance:</b> Annual echocardiogram and ECG from diagnosis</li>
            <li><b>Physical therapy:</b> Focus on maintaining mobility and preventing contractures</li>
            <li><b>Genetic counseling:</b> Important for female carriers due to X-linked inheritance</li>
        </ol>

        <h2>Complications</h2>
        <p>Major complications include:</p>
        <ol>
            <li><b>Cardiomyopathy:</b> May be the presenting feature in some cases</li>
            <li><b>Respiratory insufficiency:</b> Occurs later than in DMD</li>
            <li><b>Contractures:</b> Less severe than DMD but still problematic</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>A 12-year-old boy presents with mild proximal weakness and calf hypertrophy. His CK is 5,000 U/L. Muscle biopsy shows patchy dystrophin staining. What is the most likely molecular mechanism of his condition?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Complete absence of dystrophin due to frameshift mutation</li>
            <li data-answer="correct">Production of partially functional dystrophin due to in-frame deletion</li>
            <li data-answer="wrong">Autoantibodies against dystrophin</li>
            <li data-answer="wrong">Defective dystrophin glycosylation</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>Which of the following is the most critical difference in management between DMD and BMD?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">BMD requires more aggressive steroid therapy</li>
            <li data-answer="correct">Cardiac surveillance is equally important in BMD despite milder skeletal involvement</li>
            <li data-answer="wrong">BMD patients never develop respiratory failure</li>
            <li data-answer="wrong">BMD patients require earlier spinal fusion for scoliosis</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Facioscapulohumeral Muscular Dystrophy (FSHD)</h1>
        
        <h2>Aetiology</h2>
        <p>FSHD is caused by a <b>contraction of the D4Z4 macrosatellite repeat</b> on chromosome 4q35. Normally, there are 11-100 repeats; FSHD occurs when this is reduced to 1-10 repeats. This leads to <b>derepression of the DUX4 gene</b>, which is toxic to muscle cells.</p>

        <h2>Epidemiology</h2>
        <p>FSHD has a prevalence of about <b>1 in 20,000</b>. It shows <b>autosomal dominant</b> inheritance with nearly complete penetrance by age 20. About 30% of cases represent de novo mutations.</p>

        <h2>Pathophysiology</h2>
        <p>The D4Z4 contraction results in:</p>
        <ol>
            <li>Chromatin relaxation and <b>aberrant expression of DUX4</b></li>
            <li>DUX4 activates <b>pro-apoptotic pathways</b> and <b>inhibits muscle differentiation</b></li>
            <li>Preferential involvement of <b>facial, scapular, and humeral muscles</b></li>
        </ol>

        <h2>Symptoms and Signs</h2>
        <p>FSHD has distinct clinical features:</p>
        <ol>
            <li><b>Facial weakness:</b> Inability to whistle, drink through a straw, or fully close eyes during sleep</li>
            <li><b>Scapular winging:</b> Prominent when arms extended forward ("Mermaid sign" - inability to raise arms like a mermaid)</li>
            <li><b>Asymmetric weakness:</b> Often more pronounced on one side</li>
            <li><b>Extramuscular manifestations:</b> High-frequency hearing loss, retinal vasculopathy</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: FSHD Features</b> - <i>"Face the Scapular Hum"</i><br>
            <b>Face</b> weakness (difficulty whistling)<br>
            <b>Scapular</b> winging<br>
            <b>Hum</b>eral weakness (biceps/triceps affected early)<br>
            <b>D</b>istal leg involvement later (foot dorsiflexors)
        </div>

        <h2>Diagnosis</h2>
        <p>Diagnostic approach includes:</p>
        <ol>
            <li><b>Genetic testing:</b> Southern blot for D4Z4 repeat contraction (gold standard)</li>
            <li><b>EMG:</b> Myopathic pattern in affected muscles</li>
            <li><b>Muscle biopsy:</b> Often shows inflammatory infiltrates (may mimic myositis)</li>
            <li><b>Ancillary tests:</b> Audiometry, retinal examination</li>
        </ol>

        <h2>Treatment</h2>
        <p>Management is supportive:</p>
        <ol>
            <li><b>Physical therapy:</b> Focus on scapular stabilization exercises</li>
            <li><b>Orthotics:</b> Ankle-foot orthoses for foot drop</li>
            <li><b>Surgical:</b> Scapulothoracic fusion for severe winging</li>
            <li><b>Monitoring:</b> Annual evaluation for hearing/vision changes</li>
        </ol>

        <h2>Complications</h2>
        <p>Potential complications include:</p>
        <ol>
            <li><b>Severe facial weakness:</b> Leading to exposure keratitis</li>
            <li><b>Respiratory insufficiency:</b> In advanced cases with thoracic involvement</li>
            <li><b>Pain:</b> Myalgias and joint pain due to abnormal biomechanics</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>A 25-year-old man presents with difficulty whistling and scapular winging. His mother has similar symptoms. Which genetic test is most appropriate?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">DMD gene sequencing</li>
            <li data-answer="wrong">Mitochondrial DNA analysis</li>
            <li data-answer="correct">Southern blot for D4Z4 repeat contraction</li>
            <li data-answer="wrong">SMN1 gene deletion analysis</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>Which of the following is the pathognomonic molecular feature of FSHD?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Trinucleotide repeat expansion</li>
            <li data-answer="wrong">Mitochondrial DNA deletion</li>
            <li data-answer="correct">Contraction of D4Z4 macrosatellite repeat</li>
            <li data-answer="wrong">Autosomal recessive point mutation</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Limb-Girdle Muscular Dystrophy (LGMD)</h1>
        
        <h2>Aetiology</h2>
        <p>LGMD represents a <b>heterogeneous group</b> of disorders caused by mutations in various genes encoding proteins essential for muscle membrane stability, repair, or contractility. Over 30 subtypes exist, classified as:</p>
        <ol>
            <li><b>LGMD1:</b> Autosomal dominant forms (rare)</li>
            <li><b>LGMD2:</b> Autosomal recessive forms (more common)</li>
        </ol>
        <p>Common subtypes include:</p>
        <ol>
            <li><b>LGMD2A:</b> Calpain-3 deficiency (most common worldwide)</li>
            <li><b>LGMD2B:</b> Dysferlinopathy</li>
            <li><b>LGMD2I:</b> FKRP-related (common in Northern Europe)</li>
        </ol>

        <h2>Epidemiology</h2>
        <p>The collective prevalence is approximately <b>1 in 15,000</b>. The most common subtypes vary by population:</p>
        <ol>
            <li><b>LGMD2A:</b> Prevalent in Brazil, Italy, and Spain</li>
            <li><b>LGMD2I:</b> Common in Northern Europe</li>
            <li><b>LGMD2B:</b> Higher frequency in certain ethnic groups (e.g., Libyan Jews)</li>
        </ol>

        <h2>Pathophysiology</h2>
        <p>The mechanisms vary by subtype but generally involve:</p>
        <ol>
            <li><b>Sarcolemmal instability:</b> Due to defects in dystrophin-associated proteins (e.g., sarcoglycans in LGMD2C-F)</li>
            <li><b>Impaired membrane repair:</b> In dysferlinopathies (LGMD2B)</li>
            <li><b>Abnormal proteolysis:</b> Calpain-3 deficiency (LGMD2A) affects sarcomeric remodeling</li>
        </ol>

        <h2>Symptoms and Signs</h2>
        <p>Despite heterogeneity, shared features include:</p>
        <ol>
            <li><b>Proximal > distal weakness:</b> Affecting pelvic or shoulder girdle first</li>
            <li><b>Variable progression:</b> From mild to severe disability</li>
            <li><b>Cardiac involvement:</b> Particularly in LGMD2I (FKRP), LGMD1B (lamin A/C)</li>
            <li><b>Calf hypertrophy:</b> Seen in sarcoglycanopathies (LGMD2C-F)</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: LGMD Clues</b> - <i>"CALF DYSfunction"</i><br>
            <b>C</b>alpainopathy (LGMD2A - most common)<br>
            <b>A</b>utosomal recessive (most subtypes)<br>
            <b>L</b>imb-girdle pattern (proximal weakness)<br>
            <b>F</b>KRP (LGMD2I - cardiac involvement)<br>
            <b>DYS</b>ferlinopathy (LGMD2B - elevated CK)
        </div>

        <h2>Diagnosis</h2>
        <p>Diagnostic approach:</p>
        <ol>
            <li><b>Serum CK:</b> Typically elevated (5-50x normal), highest in dysferlinopathies</li>
            <li><b>Muscle biopsy:</b> Immunohistochemistry can identify specific protein deficiencies</li>
            <li><b>Genetic testing:</b> Targeted panels or whole exome sequencing</li>
            <li><b>Cardiac evaluation:</b> ECG and echocardiogram in selected subtypes</li>
        </ol>

        <h2>Treatment</h2>
        <p>Management is subtype-specific but generally includes:</p>
        <ol>
            <li><b>Physical therapy:</b> To maintain mobility and prevent contractures</li>
            <li><b>Cardiac monitoring:</b> Especially in subtypes with known cardiac risk</li>
            <li><b>Respiratory support:</b> Nocturnal ventilation if needed</li>
            <li><b>Experimental therapies:</b> Gene therapy trials ongoing for certain subtypes</li>
        </ol>

        <h2>Complications</h2>
        <p>Potential complications include:</p>
        <ol>
            <li><b>Severe disability:</b> Loss of ambulation in some subtypes</li>
            <li><b>Respiratory failure:</b> Due to diaphragmatic weakness</li>
            <li><b>Cardiomyopathy:</b> Particularly in LGMD2I and LGMD1B</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>A 20-year-old woman presents with progressive difficulty climbing stairs and rising from chairs. Her CK is 8,000 U/L. Muscle biopsy shows deficiency of calpain-3. What is the most likely LGMD subtype?</p>
        <ul class="options" id="options">
            <li data-answer="correct">LGMD2A</li>
            <li data-answer="wrong">LGMD2B</li>
            <li data-answer="wrong">LGMD2I</li>
            <li data-answer="wrong">LGMD1C</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>Which LGMD subtype is most strongly associated with cardiomyopathy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">LGMD2A (calpainopathy)</li>
            <li data-answer="wrong">LGMD2B (dysferlinopathy)</li>
            <li data-answer="correct">LGMD2I (FKRP-related)</li>
            <li data-answer="wrong">LGMD2D (α-sarcoglycanopathy)</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Myotonic Dystrophy Type 1 and 2 (DM1/2)</h1>
        
        <h2>Aetiology</h2>
        <p>Myotonic dystrophies are <b>multisystem trinucleotide repeat disorders</b>:</p>
        <ol>
            <li><b>DM1:</b> Caused by CTG repeat expansion in <b>DMPK</b> gene on 19q13.3</li>
            <li><b>DM2:</b> Caused by CCTG repeat expansion in <b>CNBP</b> gene on 3q21</li>
        </ol>
        <p>The expansions lead to <b>RNA toxicity</b> affecting splicing of multiple other genes.</p>

        <h2>Epidemiology</h2>
        <p><b>DM1</b> has a prevalence of 1 in 8,000, while <b>DM2</b> is rarer (1 in 20,000). DM1 shows <b>anticipation</b> (worsening in successive generations), especially when inherited maternally.</p>

        <h2>Pathophysiology</h2>
        <p>The expanded RNA forms <b>nuclear foci</b> that sequester RNA-binding proteins, leading to:</p>
        <ol>
            <li><b>Mis-splicing</b> of multiple transcripts (e.g., CLCN1, INS)</li>
            <li><b>Muscle membrane hyperexcitability</b> (causing myotonia)</li>
            <li><b>Multisystem involvement</b> due to widespread splicing defects</li>
        </ol>

        <h2>Symptoms and Signs</h2>
        <p>DM1 and DM2 share features but differ in severity:</p>
        <ol>
            <li><b>Myotonia:</b> Delayed relaxation after contraction (e.g., handgrip, percussion)</li>
            <li><b>Distal weakness:</b> DM1 affects hands, ankles; DM2 more proximal</li>
            <li><b>Extramuscular:</b> Cataracts, cardiac conduction defects, insulin resistance, frontal balding</li>
            <li><b>Congenital DM1:</b> Severe form with hypotonia, respiratory failure at birth</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: DM1 Features</b> - <i>"D.M. 1-2-3"</i><br>
            <b>D</b>istal weakness<br>
            <b>M</b>yotonia<br>
            <b>1</b>9q (chromosome location)<br>
            <b>2</b>nd most common adult MD (after FSHD)<br>
            <b>3</b>'s: Cataracts, Cardiac, Cognitive
        </div>

        <h2>Diagnosis</h2>
        <p>Diagnostic approach:</p>
        <ol>
            <li><b>Genetic testing:</b> PCR/Southern blot for repeat expansions</li>
            <li><b>EMG:</b> Shows myotonic discharges ("dive bomber" sound)</li>
            <li><b>Slit lamp:</b> Early posterior subcapsular cataracts</li>
            <li><b>Cardiac:</b> Holter monitoring for conduction abnormalities</li>
        </ol>

        <h2>Treatment</h2>
        <p>Management focuses on symptom control:</p>
        <ol>
            <li><b>Myotonia:</b> Mexiletine (first-line), carbamazepine</li>
            <li><b>Cardiac:</b> Pacemaker for significant conduction defects</li>
            <li><b>Endocrine:</b> Diabetes screening and management</li>
            <li><b>Respiratory:</b> Nocturnal ventilation if needed</li>
        </ol>

        <h2>Complications</h2>
        <p>Serious complications include:</p>
        <ol>
            <li><b>Sudden cardiac death:</b> Due to arrhythmias</li>
            <li><b>Respiratory failure:</b> Both restrictive and central hypoventilation</li>
            <li><b>Anesthetic risks:</b> Increased sensitivity to sedatives and paralytics</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 11</h1>
        <p>A 40-year-old man presents with grip myotonia and bilateral ptosis. Genetic testing shows CTG repeat expansion. Which gene is affected?</p>
        <ul class="options" id="options">
            <li data-answer="correct">DMPK</li>
            <li data-answer="wrong">CNBP</li>
            <li data-answer="wrong">DMD</li>
            <li data-answer="wrong">SMN1</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 12</h1>
        <p>Which of the following is the most characteristic EMG finding in myotonic dystrophy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Fibrillation potentials</li>
            <li data-answer="wrong">Complex repetitive discharges</li>
            <li data-answer="correct">Waxing-waning myotonic discharges</li>
            <li data-answer="wrong">Positive sharp waves</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>